Chabado Genomics INC

Chabado Genomics INC was paid $325K by Medicaid between Jan 2018 and Dec 2023, across 31 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 37% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#262 of 561

Median peer was paid$222K

This provider vs. median1.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	15,263	$9K
2019	4,614	$32K
2020	951	$1K
2021	1,341	$27K
2022	6,593	$178K
2023	9,560	$78K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	37%	5,184	5,074	$121K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	17%	2,056	1,971	$56K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.9%	2,173	2,133	$32K
87150		5.1%	335	320	$17K
87631		4.2%	484	478	$14K
82043		2.6%	3,398	3,327	$8K
87486		2.4%	1,848	1,844	$8K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	2.0%	216	215	$7K
87481		1.7%	171	168	$6K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.6%	182	182	$5K
87529		1.6%	216	215	$5K
87634		1.5%	214	213	$5K

19 more codes

80299		1.2%	3,284	$4K
84133		1.2%	4,550	$4K
84300		1.1%	4,521	$4K
87500		1.1%	297	$4K
87581		1.0%	1,849	$3K
87498		<1%	215	$3K
87541		<1%	278	$3K
87640		<1%	214	$3K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,561	$3K
87652		<1%	171	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	214	$2K
87641		<1%	171	$2K
82436		<1%	1,461	$1K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	59	$890.50
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	40	$589.24
82945		<1%	1,533	$355.68
0099U		<1%	204	$330.00
87507		<1%	121	$44.45
82042		<1%	1,102	$13.40

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLEE, GIA (ADMINISTRATOR)

Same official

Other billing entities under LEE, GIA

Full network →

Provider	Location	Paid
L&L Diagnostics LLC	Covina, CA	$1.63M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.